We are live on ! Find out more
TTP

TITAN PHARMACEUTICAL INC
TTP

Delisted

TTP was delisted on the 24th of December, 2008.

2 hedge funds and large institutions have $153K invested in TITAN PHARMACEUTICAL INC in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 22 (0)

59% less capital invested

Capital invested by funds: $377K → $153K (-$224K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
Holders Change %
0%
% of All Funds
0.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
1
Closed
Calls
Puts
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
GS
Gagnon Securities
New York
-$103K
Name Holding Trade Value Shares
Change
Change in
Stake
GS
1
Gagnon Securities
New York
$144K -$103K -25,756 -42%
VIA
2
Vantage Investment Advisors
Pennsylvania
$9K

TTP Hedge Fund Activity: Q4 2016 in Review

2 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in TITAN PHARMACEUTICAL INC (TTP) for Q4 2016, worth a combined $153K — down 59% from $377K a quarter earlier.

Fund positioning in TTP was balanced in Q4 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was Gagnon Securities, cutting an estimated $103K.

  • 2 institutional investors held TITAN PHARMACEUTICAL INC (TTP) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $153K of TITAN PHARMACEUTICAL INC stock for Q4 2016, down 59% quarter-over-quarter.
  • 0 funds opened new TITAN PHARMACEUTICAL INC positions in Q4 2016 and 0 closed out.
  • The largest TITAN PHARMACEUTICAL INC seller in Q4 2016 was Gagnon Securities, an estimated $103K sold.

Based on aggregated 13F filings for Q4 2016.